Edition:
India

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

0.65USD
22 Nov 2017
Change (% chg)

$0.03 (+4.00%)
Prev Close
$0.62
Open
$0.63
Day's High
$0.66
Day's Low
$0.60
Volume
126,371
Avg. Vol
63,845
52-wk High
$2.40
52-wk Low
$0.32

Chart for

About

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $11.85
Shares Outstanding(Mil.): 23.25
Dividend: --
Yield (%): --

Financials

BRIEF-RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​

* RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​

13 Nov 2017

BRIEF-RXi Pharmaceuticals reports Q3 2017 financial results and recent corporate highlights

* Reports third quarter 2017 financial results and recent corporate highlights

08 Nov 2017

BRIEF-RXi Pharmaceuticals files for sale of up to 7.3 mln shares

* RXi Pharmaceuticals Corp- files for sale of up to 7.3 million shares of common stock by Lincoln Park Capital Fund Llc - SEC filing‍​ Source text: (http://bit.ly/2vQLno4) Further company coverage:

19 Aug 2017

Earnings vs. Estimates